Cargando…

Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N Mutation

Ivacaftor has been shown to restore the functionality of the S1251N (also known as c.3752G>A) mutated CFTR, which may cause alterations in both airway and gut physiology and micro-environment, resulting in a change of microbiota in these organs. The aim of the present study was to analyze the eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kristensen, Maartje I., de Winter-de Groot, Karin M., Berkers, Gitte, Chu, Mei Ling J. N., Arp, Kayleigh, Ghijsen, Sophie, Heijerman, Harry G. M., Arets, Hubertus G. M., Majoor, Christof J., Janssens, Hettie M., van der Meer, Renske, Bogaert, Debby, van der Ent, Cornelis K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146888/ https://www.ncbi.nlm.nih.gov/pubmed/33925519 http://dx.doi.org/10.3390/jpm11050350

Ejemplares similares

Long‐term effects of ivacaftor on nonpulmonary outcomes in individuals with cystic fibrosis, heterozygous for a S1251N mutation
por: Burghard, M (Marcella), et al.
Publicado: (2020)

The impact of ivacaftor on sinonasal pathology in S1251N-mediated cystic fibrosis patients
por: Gostelie, Romee, et al.
Publicado: (2020)

Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators
por: Muilwijk, Danya, et al.
Publicado: (2021)

Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability
por: Vonk, Steffie E. M., et al.
Publicado: (2021)

CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare CFTR Genotypes
por: Lefferts, Juliet W., et al.
Publicado: (2023)

Ivacaftor Therapy in CF Patients: Single Center Experience
por: Mondal, Pritish, et al.
Publicado: (2014)

16S rRNA-Based Microbiota Profiling Assists Conventional Culture Analysis of Airway Samples from Pediatric Cystic Fibrosis Patients
por: Kristensen, Maartje, et al.
Publicado: (2023)

Home videos of cystic fibrosis patients using tobramycin inhalation powder: Relation of flow and cough
por: Meerburg, Jennifer J., et al.
Publicado: (2019)

Rapid early increase in BMI is associated with impaired longitudinal growth in children with cystic fibrosis
por: Hak, Sarah F., et al.
Publicado: (2019)

Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults
por: Kim, Jeeyeon, et al.
Publicado: (2018)

Rectal swabs are a reliable proxy for faecal samples in infant gut microbiota research based on 16S-rRNA sequencing
por: Reyman, Marta, et al.
Publicado: (2019)

Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients
por: Neerincx, Anne H., et al.
Publicado: (2021)

Pharmacokinetics and safety of tobramycin nebulization with the I‐neb and PARI‐LC Plus in children with cystic fibrosis: A randomized, crossover study
por: van Velzen, Annelies J., et al.
Publicado: (2019)

Infection, inflammation and exercise in cystic fibrosis
por: van de Weert-van Leeuwen, Pauline Barbera, et al.
Publicado: (2013)

Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype delta F508/S1215N
por: Berkhout, Maaike, et al.
Publicado: (2015)

CFTR Modulators: Does One Dose Fit All?
por: van der Meer, Renske, et al.
Publicado: (2021)

1251. Determinants of Infection at a Nontransplanting Cardiothoracic LVAD Program
por: Milgrom, Alexander, et al.
Publicado: (2019)

Real‐life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients
por: Kos, Renate, et al.
Publicado: (2022)

1251. Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

1251. Strengthening Antimicrobial Stewardship Programs through Public Health Support
por: Kriengkauykiat, Jane, et al.
Publicado: (2023)

Simultaneous hyperaccumulation of nickel and cobalt in the tree Glochidion cf. sericeum (Phyllanthaceae): elemental distribution and chemical speciation
por: van der Ent, Antony, et al.
Publicado: (2018)

Microbial community networks across body sites are associated with susceptibility to respiratory infections in infants
por: Reyman, Marta, et al.
Publicado: (2021)

Survival and prognosis after assisted ventilation for acute respiratory failure in cystic fibrosis
por: van Gestel, S, et al.
Publicado: (2005)

P1251: BONE-BASED 3D SCAFFOLD AS AN IN-VITRO MODEL OF MICROENVIRONMENT-LYMPHOMA INTERACTION
por: Ceccato, J., et al.
Publicado: (2022)

The respiratory microbiota during and following mechanical ventilation for respiratory infections in children
por: de Koff, Emma M., et al.
Publicado: (2021)

Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation
por: Rowe, Steven M., et al.
Publicado: (2013)

A Descriptive Analysis of 1251 Solid Organ Transplant Visits to the Emergency Department
por: Unterman, Sarah, et al.
Publicado: (2009)

A Case Report of Pulmonary Exacerbation after Initiation of Lumacaftor/Ivacaftor Therapy in a CF Female with Complicated Lung Disease
por: Hatziagorou, Elpis, et al.
Publicado: (2018)

Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score
por: Mainz, Jochen G., et al.
Publicado: (2022)

Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score
por: Mainz, Jochen G., et al.
Publicado: (2023)

ROCK STUDY in CF: sustained anti-inflammatory effects of lumacaftor–ivacaftor in sputum and peripheral blood samples of adult patients with cystic fibrosis—an observational study
por: Arooj, Parniya, et al.
Publicado: (2023)

Ivacaftor, not ivacaftor/lumacaftor, associated with lower pulmonary inflammation in preschool cystic fibrosis
por: Shanthikumar, Shivanthan, et al.
Publicado: (2022)

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
por: Pilewski, Joseph M., et al.
Publicado: (2020)

Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events
por: Schwarz, Carsten, et al.
Publicado: (2021)

Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation
por: Burghard, Marcella, et al.
Publicado: (2022)

Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome
por: Marsh, Ryan, et al.
Publicado: (2023)

Development and validation of a novel personalized electronic patient-reported outcome measure to assess quality of life (Q-LIFE): a prospective observational study in people with Cystic Fibrosis
por: Muilwijk, Danya, et al.
Publicado: (2023)

Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Lumacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Effect of Long-Term Voluntary Exercise Wheel Running on Susceptibility to Bacterial Pulmonary Infections in a Mouse Model
por: van de Weert – van Leeuwen, Pauline B., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_pr8nm617s7pb02o8c5rdi5f28o